Besse Benjamin, Spano Jean-Philippe
Département de médecine, Institut Gustave-Roussy, 94805 Villejuif.
Bull Cancer. 2002 Aug;89 Spec No:S107-14.
Gemcitabine has demonstrated a good efficacy in number of tumor types. Thanks to its favourable toxicity profile, gemcitabine can be used in combination with a number of drugs. Single agent gemcitabine and gemcitabine-based combinations have been evaluated in metastatic breast cancer. Some of these combinations, such as gemcitabine-vinorelbine, seem highly efficacious in patients with taxane and/or anthracycline refractory disease. Other combinations such as gemcitabine-anthracycline-taxane regimens were found to be highly effective in the neoadjuvant setting or as first line treatment for metastatic breast cancer. Some of the combinations tested deserve further evaluation in phase III trials. Several phase III trials are in progress in Europe and in the USA. Final judgment on the contribution of gemcitabine will not be made until the results of these further studies become available.
吉西他滨已在多种肿瘤类型中显示出良好疗效。由于其良好的毒性特征，吉西他滨可与多种药物联合使用。单药吉西他滨及以吉西他滨为基础的联合用药方案已在转移性乳腺癌中进行了评估。其中一些联合用药，如吉西他滨 - 长春瑞滨，在对紫杉烷和/或蒽环类药物耐药的患者中似乎疗效显著。其他联合用药方案，如吉西他滨 - 蒽环类药物 - 紫杉烷方案，在新辅助治疗或作为转移性乳腺癌的一线治疗中被发现非常有效。一些测试的联合用药方案值得在III期试验中进一步评估。欧洲和美国正在进行多项III期试验。在这些进一步研究的结果出来之前，无法对吉西他滨的作用做出最终判断。
